Biomedical application | ООО "Миллисекундные Технологии"
Modern advanced healthcare has reached remarkable results. Not so long ago incurable diseases, in particular, cancer of various organs and tissue, with the help of chemical therapy and surgery, including transplant surgery have become curable. Not least the results achieved were made possible through the utilization of the methods of blood components replacement transfusion therapy, which is used in all of the applied procedures.
At the same time the widening use of donor blood components has made even more acute the need for the prevention of transmission of deadly haemo transmissible infections, mainly of virus nature (AIDS, hepatitis B and C). This is why there is some much interest in developing new, more efficient methods of pathogen inactivation of blood components, in particular plasma – the most widely used transfusion medium.
Existing methods for verification and inactivation of blood component’s pathogens, which include screening and selection of donors, quarantining, pasteurization as well as chemical technologies for treating blood cells and plasma, do not eliminate the risk of transfusion of a infected medium. In addition to that existing technologies reduce the effectiveness of the transfused mediums, are expensive, and in the majority of cases are being imported into our country.
MST technology being developed by us envisages a completely different approach to pathogen inactivation. For the first time in medical practice it is based on physically influencing pathogens by two complimentary factors – short period (millisecond) change in pressure and rapid heating of the product in a special chamber. The preliminary lab tests of the MST technology have shown possibility of reducing the pathogen count by 4-6 logs while maintain high level of preservation and activity of the most important blood plasma proteins.